LauraJeanJohnstonMD

Hematology • Stanford, CA

Hematologic Oncology

Associate Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to view full profile

Dr. Johnston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Johnston's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-725-8950

Education & Training

University of California (San Francisco)/FresnoFellowship, Hematology and Medical Oncology, 1995
University of California (San Francisco)Internship, Internal Medicine, 1989 - 1990
University of Minnesota Medical SchoolClass of 1989

Certifications & Licensure

CA State Medical License 1990 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Bone Marrow Grafting for Leukemia and Lymphoma Start of enrollment: 1988 Mar 01
Enrolling by invitation
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
Completed
Phase 1, Phase 2
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Start of enrollment: 2008 Oct 01
Completed
Phase 3
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Start of enrollment: 2019 Aug 15
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston
American Journal of Hematology. 2024-08-01
4 citations
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh
Leukemia. 2024-05-01
4 citations
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.
Cameron S Bader, Anna Pavlova, Robert Lowsky, Lori S Muffly, Parveen Shiraz
Blood Advances. 2024-03-12

Abstracts/Posters

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Laura J Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019